James Ahlers
Corporate Officer/Principal bij INTENSITY THERAPEUTICS, INC.
Vermogen: - $ op 30-04-2024
Profiel
James M.
Ahlers is currently the Executive Vice President-Corporate Finance at Intensity Therapeutics, Inc. Prior to his current position, he held various roles including Director-Finance & Administration at Titan Pharmaceuticals, Inc. and Ansan Pharmaceuticals, Inc., Financial Consultant at Tularik, Inc., Genesoft Pharmaceuticals, Inc., and Cytokinetics, Inc., and Chief Financial Officer at RenovoRx, Inc. from 2022 to 2024.
He also worked as a Member-Audit Department at Deloitte & Touche LLP and Manager-Financial Planning & Analysis at Medco Behavioral Care Corp.
Additionally, Mr. Ahlers served as the Chief Financial Officer and VP-Operations & Finance at Intarcia Therapeutics, Inc. from 2002 to 2019.
He completed his undergraduate degree at the University of San Francisco.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 01-03-2024 | 0 ( -.--% ) | - $ | 30-04-2024 |
Actieve functies van James Ahlers
| Bedrijven | Functie | Begin |
|---|---|---|
| INTENSITY THERAPEUTICS, INC. | Corporate Officer/Principal | 01-06-2023 |
Eerdere bekende functies van James Ahlers
| Bedrijven | Functie | Einde |
|---|---|---|
| RENOVORX, INC. | Financieel Directeur/CFO | 05-02-2024 |
Intarcia Therapeutics, Inc.
 Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Financieel Directeur/CFO | 01-11-2019 |
Deloitte & Touche LLP
 Deloitte & Touche LLP Miscellaneous Commercial ServicesCommercial Services Deloitte & Touche LLP engages in the provision of audit, advisory, financial advisory, tax, and consulting services. The company was founded on March 7, 1995 and is headquartered in New York, NY. | Corporate Officer/Principal | - |
Tularik, Inc.
 Tularik, Inc. Miscellaneous Commercial ServicesCommercial Services Tularik, Inc. is engaged in the discovery and development of a broad range of novel and superior orally available medicines that act through the regulation of gene expression. Tularik's scientific platform is focused on three therapeutic areas: cancer, inflammation and metabolic disease. The company was founded in 1991 and is headquartered in South San Francisco, CA. | Corporate Officer/Principal | - |
| Genesoft Pharmaceuticals, Inc. | Corporate Officer/Principal | - |
Opleiding van James Ahlers
| University of San Francisco | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 4 |
|---|---|
| TITAN PHARMACEUTICALS, INC. | Health Technology |
| CYTOKINETICS, INCORPORATED | Health Technology |
| INTENSITY THERAPEUTICS, INC. | Health Technology |
| RENOVORX, INC. | Health Technology |
| Bedrijven in privébezit | 6 |
|---|---|
Tularik, Inc.
Tularik, Inc. Miscellaneous Commercial ServicesCommercial Services Tularik, Inc. is engaged in the discovery and development of a broad range of novel and superior orally available medicines that act through the regulation of gene expression. Tularik's scientific platform is focused on three therapeutic areas: cancer, inflammation and metabolic disease. The company was founded in 1991 and is headquartered in South San Francisco, CA. | Commercial Services |
| Genesoft Pharmaceuticals, Inc. | Commercial Services |
Deloitte & Touche LLP
Deloitte & Touche LLP Miscellaneous Commercial ServicesCommercial Services Deloitte & Touche LLP engages in the provision of audit, advisory, financial advisory, tax, and consulting services. The company was founded on March 7, 1995 and is headquartered in New York, NY. | Commercial Services |
Medco Behavioral Care Corp.
 Medco Behavioral Care Corp. Pharmaceuticals: MajorHealth Technology Medco Behavioral Care Corp. specializes in behavioral health management. | Health Technology |
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Health Technology |
| Ansan Pharmaceuticals, Inc. | Health Technology |
